XGN: Multiplikator P/S Exagen Inc

Demand for autoimmune pathology diagnostics is steadily growing, expanding the client base of Exagen Inc. On GURU.Markets, the P/S ratio history demonstrates the market valuation of the business, where the 1.40 level indicates the status of the parameter. The company's resilience is based on system redundancy in its California laboratory, while biomarker patents and high accreditation standards create significant barriers to entry for new players.

The P/S ratio compares the market capitalization of Exagen Inc. (XGN) to its annual revenue, allowing for a valuation of the business relative to generated cash flows regardless of profit. The price-to-sales trend reflects market expectations for the expansion of the rheumatologist base and demand for diagnostics, where deviations from industry norms signal either an overvaluation or an undervaluation of the asset.